このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

PROMOTE: Effects of 5-HT4 Agonism on Cognition and Sleep in Peopl With Low Mood (PROMOTE)

2026年10月1日 更新者:University of Oxford

Investigating the Effect of 5-HT4 Receptor Agonism on Cognition and Sleep in People With Low Mood

Serotonin is a chemical in the brain that plays an important role in mood, sleep, and other functions. It works by attaching to different types of serotonin receptors on brain cells. These receptors act like "locks", with serotonin acting like a "key". Different types of serotonin receptors have different effects in the brain.

Prucalopride is a licensed medication used to treat constipation. It acts on a particular serotonin receptor, called the serotonin 4 receptor. Researchers are interested in this receptor because understanding how it works in the brain may help us learn more about depression and could contribute to the development of new treatments in the future.

The purpose of this study is to investigate the effects of prucalopride in people experiencing low mood. We will compare prucalopride with a placebo (a treatment with no active medication) to find out whether activating the serotonin 4 receptor affects sleep and aspects of thinking, including memory, attention and decision making.

調査の概要

状態

まだ募集していません

詳細な説明

Cognitive symptoms are common in depression and can persist even when other symptoms of depression have improved. These difficulties can include impairments in memory, attention and executive function, and there remains a need for treatments that specifically target cognitive dysfunction associated with depression.

Evidence from preclinical and human experimental studies suggests that activation of the serotonin 4 receptor (5-HT4R) may represent a potential therapeutic approach for targeting cognitive symptoms in depression. The 5-HT4R is expressed in brain regions involved in learning and memory, and experimental studies have investigated whether selective activation of this receptor can influence cognitive processes relevant to depression.

Prucalopride is a selective 5-HT4R agonist. In previous human experimental studies, we have found evidence that prucalopride can influence cognitive processes, including learning and memory, in healthy volunteers and people who have recovered from depression. The present study extends this work by investigating the cognitive effects of prucalopride in people who are currently experiencing low mood.

The study will use an experimental medicine approach to examine the effects of 5-HT4R activation on cognitive processes relevant to depression. In addition, the study will investigate the effect of prucalopride on sleep architecture. Sleep will be assessed in the home environment using wearable chest patches capable of sleep staging.

The study will provide proof-of-concept evidence regarding the effects of 5-HT4R activation on cognition and sleep in people experiencing low mood. These data will inform the design and feasibility of a future randomised controlled trial evaluating prucalopride in people with depression and cognitive impairment.

研究の種類

介入

入学 (推定)

60

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Oxfordshire
      • Oxford、Oxfordshire、イギリス、OX3 7JX
        • Warneford Hospital
        • 主任研究者:
          • Susannah E Murphy, DPhil
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~65年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Aged between 18-65
  • Male or female
  • Participant is willing and able to give informed consent for participation in the research
  • Body mass index in the range of 18-35 inclusive
  • Current PHQ-9 score in the range of 9-15

Exclusion Criteria:

  • Any current or previous episode of a severe mental illness, other than Depressive Disorder. Comorbid Anxiety disorders will be allowed, but not OCD or PTSD.
  • A first degree relative diagnosed with Bipolar Affective Disorder Type 1 or Schizophrenia
  • Body Mass Index outside the range of 18 to 35 inclusive
  • Any significant current medical condition likely to interfere with conduct of the study or analysis of data
  • Current use of psychoactive and / or medically significant medication as judged by a study medic, whether prescribed or bought over the counter (the contraceptive pill, the Depo-Provera injection or the progesterone implant will not result in exclusion)
  • Ongoing psychopharmacological treatment for depression, including hypnotics (psychotherapy will be allowed as long as not newly-started in the last 6 weeks)
  • High consumption of illicit substances to an extent that would make complying with study protocol challenging (including alcohol, caffeine, nicotine)
  • Past history of dependence to illicit substances, and any consumption of illicit substances in the three months prior to the study
  • Currently pregnant, trying to get pregnant, or breast feeding
  • Current, or a significant history of, gastro-intestinal disorder or irritable bowel syndrome
  • Known lactase deficiency or any other problem absorbing lactose, galactose, or glucose
  • Participation in a study that involves the use of a medication or novel vaccine within the last three months
  • Participation in a study using the same tasks in the last year
  • Any physical (including visual and auditory) or language impairment that would make complying with the study protocol challenging, including yellow/blue colourblindness
  • A head injury causing concussion or loss of consciousness within the last six months
  • Moderate to high risk of suicide or self-harm
  • Participant who is unlikely to comply with the clinical study protocol or is unsuitable for any other reason, in the opinion of the Chief Investigator.

Additional Exclusion Criteria for Participants in the Sleep Study Cohort:

  • Unable to undergo cardiac monitoring
  • Unable to wear the sleep patch device for full monitoring period
  • Implanted neurostimulator or pacemaker

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:基礎科学
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Prucalopride

Participants will receive daily oral prucalopride for 14 days.

Prucalopride will be administered orally once daily for 14 days. Participants will receive 1 mg once daily on Days 1-2 and 2 mg once daily on Days 3-14.

プラセボコンパレーター:Placebo

Participants will receive daily oral placebo for 14 days.

A matching placebo (lactose) will be administered orally once daily for 14 days. Participants will take one placebo capsule on Days 1-2 and two placebo capsules on Days 3-14, matching the dosing schedule of the prucalopride intervention.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Auditory Verbal Learning Test (AVLT)
時間枠:Day 14 (post-intervention)

Verbal learning and memory will be assessed using the Auditory Verbal Learning Test, including measures of immediate recall, delayed recall, and recognition memory. AVLT performance will be compared between prucalopride and placebo groups following the intervention.

Day 14 (post-intervention)

二次結果の測定

結果測定
メジャーの説明
時間枠
Sleep outcomes measured using wearable sleep monitoring
時間枠:Baseline (Day 0) and Days 1-4 of the intervention

Sleep will be assessed using a wearable chest patch in a subset of participants (n=20 total, 10 per intervention group). Measures will include sleep duration, sleep quality and sleep staging. Sleep outcomes will be compared between the prucalopride and placebo groups.

Baseline (Day 0) and Days 1-4 of the intervention
Digit Span Task
時間枠:Baseline and Day 14 (post-intervention)

Maximum digit span will be assessed as a measure of working memory and compared between the prucalopride and placebo groups

Baseline and Day 14 (post-intervention)
Emotional Go/No-Go (EGNG)
時間枠:Day 14 (post-intervention)

Inhibitory control will be assessed using the EGNG task, including measures of commission errors, omission errors, and reaction time. Performance will be compared between prucalopride and placebo groups follwing the intervention.

Day 14 (post-intervention)
Probabilistic Reversal Learning Task (PRL)
時間枠:Day 14 (post-intervention)

Cognitive flexibility and reward-based learning will be assessed using the PRL task, including measures such as response accuracy, reversal errors, and sensitivity to reward and punishment. Performance will be compared between prucalopride and placebo groups following the intervention.

Day 14 (post-intervention)
Mnemonic Similarity Task (MST)
時間枠:Day 14 (post-intervention)

Pattern separation and recognition memory will be assessed using the MST. Performance will be compared between the prucalopride and placebo groups following the intervention.

Day 14 (post-intervention)
Serial Addition Task (SAT)
時間枠:Day 14 (post-intervention)

Working memory will be assessed using the SAT. Performance will be compared between the prucalopride and placebo groups following the intervention

Day 14 (post-intervention)
Matrix Span Task
時間枠:Baseline and Days 2, 3, 5, 6, 8, 10, 11 and 13 of the 14-day intervention.

Visual working memory assessed using the Matrix Span Task, administered remotely via the NeuroUX app. Performance (accuracy/reaction time) will be compared between prucalopride and placebo groups.

Baseline and Days 2, 3, 5, 6, 8, 10, 11 and 13 of the 14-day intervention.
Variable Difficulty List Memory Test (VDLMT)
時間枠:Baseline and Days 1, 2, 4, 6, 7, 9, 11, 12 and 14 of the 14-day intervention.

Verbal learning and recognition memory will be assessed using the VDLMT, administered remotely via the NeuroUX app. Performance will be compared between the prucalopride and placebo groups.

Baseline and Days 1, 2, 4, 6, 7, 9, 11, 12 and 14 of the 14-day intervention.
N-Back Test
時間枠:Baseline and Days 1, 3, 4, 6, 8, 9, 11, 13 and 14 of the 14-day intervention.

Working memory will be assessed using the 2-back version of the N-back task, administered remotely via the NeuroUX app. Performance will be compared between the prucalopride and placebo groups.

Baseline and Days 1, 3, 4, 6, 8, 9, 11, 13 and 14 of the 14-day intervention.
Digit Symbol Substitution Task (DSST)
時間枠:Baseline and Days 1, 3, 5, 7, 8, 10, 12 and 13 of the 14-day intervention.

Processing speed will be assessed using the DSST, administered remotely via the NeuroUX app. Performance will be compared between the prucalopride and placebo groups.

Baseline and Days 1, 3, 5, 7, 8, 10, 12 and 13 of the 14-day intervention.
Quick Tap 2 Test
時間枠:Baseline and Days 2, 4, 5, 7, 9, 10, 12 and 14 of the 14-day intervention.

Response inhibition will be assessed using the Quick Tap 2 test, a go/no-go task administered remotely via the NeuroUX app. Performance will be compared between the prucalopride and placebo groups.

Baseline and Days 2, 4, 5, 7, 9, 10, 12 and 14 of the 14-day intervention.
Paired Associates Learning (PAL)
時間枠:Day 14 (post-intervention)

Verbal associative and episodic memory will be assessed using the PAL task. Performance will be compared between the prucalopride and placebo groups.

Day 14 (post-intervention)

その他の成果指標

結果測定
メジャーの説明
時間枠
State Subjective Cognition Scale (SSCS)
時間枠:Baseline and daily during the 14-day intervention.

Subjective cognitive functioning will be assessed using the State Subjective Cognition Scale (SSCS). Responses will be compared between the prucalopride and placebo groups.

Baseline and daily during the 14-day intervention.
Positive and Negative Affect Schedule (PANAS)
時間枠:Baseline and daily during the 14-day intervention.

Positive and negative affect will be assessed using the PANAS. Scores will be compared between the prucalopride and placebo groups.

Baseline and daily during the 14-day intervention.
Patient Health Questionnaire-9 (PHQ-9)
時間枠:Baseline, Day 7 and Day 14 of the intervention

Depressive symptoms will be assessed using the PHQ-9. Scores will be compared between the prucalopride and placebo groups.

Baseline, Day 7 and Day 14 of the intervention
Perceived Deficits Questionnaire (PDQ)
時間枠:Baseline, Day 7 and Day 14 of the intervention

Subjective cognitive difficulties will be assessed using the PDQ. Scores will be compared between the prucalopride and placebo groups.

Baseline, Day 7 and Day 14 of the intervention
Generalized Anxiety Disorder-7 (GAD-7)
時間枠:Baseline, Day 7 and Day 14 of the intervention.

Anxiety symptoms will be assessed using the GAD-7. Scores will be compared between the prucalopride and placebo groups.

Baseline, Day 7 and Day 14 of the intervention.
Temporal Experience of Pleasure Scale (TEPS)
時間枠:Baseline, Day 7 and Day 14 of the intervention.

Anticipatory and consummatory pleasure will be assessed using the TEPS. Scores will be compared between the prucalopride and placebo groups.

Baseline, Day 7 and Day 14 of the intervention.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Susannah E Murphy, DPhil、Department of Psychiatry, University of Oxford

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年10月1日

一次修了 (推定)

2028年7月1日

研究の完了 (推定)

2028年7月1日

試験登録日

最初に提出

2026年9月23日

QC基準を満たした最初の提出物

2026年9月23日

最初の投稿 (実際)

2026年9月30日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月6日

QC基準を満たした最後の更新が送信されました

2026年10月1日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Anonymised individual participant data (IPD) that underlie the results reported in publications arising from this study will be available to researchers upon request, subject to appropriate ethical, data protection and institutional requirements

IPD 共有時間枠

Available following the publication of the study results

IPD 共有アクセス基準

Available to researchers on request, subject to approal by the study team/institution and applicable ethical and data protection requirements

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する